key: cord-0792138-y5y9zck5
authors: Ozkan, Judy
title: Trying times for heart failure trials during the COVID-19 pandemic: American heart failure specialist William T. Abraham of the Wexler Medical Centre of Ohio State University talks to CardioPulse about the ramifications of the COVID-19 pandemic in relation to ongoing and future heart failure (HF) studies, and outlines some guiding principles and possible solutions
date: 2020-05-07
journal: Eur Heart J
DOI: 10.1093/eurheartj/ehaa378
sha: 8929f10ee6e27f3ab27660fc92be386a4890013d
doc_id: 792138
cord_uid: y5y9zck5

nan

Since the outbreak of the pandemic in early 2020, Abraham has seen major ramifications for many of the clinical trials he is currently involved in as well as implications for future trials. These will affect all of those involved in research in any capacity, and it is suggested that those involved in HF studies should consider strategies to adapt ongoing work and plan for future contingency.

He says: 'The implications of the COVID-19 pandemic extend to every current and future clinical trial and impact all those involved in them, be they funders, participants, investigators, or regulators. The implications for the heart failure community are profound. For all intents and purposes, involvement in clinical trials has mostly and appropriately stopped. We are now very focused on preserving the integrity of ongoing studies and making sure that we get as much follow-up data on schedule as possible, to ensure that we minimize the risk of missing data'.

Abraham is among several investigators seeking to address challenging issues and establish guiding principles for those involved in this sector for the duration of the global pandemic. In a collaboratory statement published in JACC Heart Failure, in March 2020, the authors outline possible solutions specifically relating to HF clinical trials. 1 The statement underscores the core principle that the safety of HF trial participants and research teams is of paramount importance. The knock-on effect of putting safety first and observing appropriate social distancing is that in-person attendance at many of the HF trial sites has effectively ceased in relation to researchers and participants.

The statement offers guidance and highlights the following possible solutions:

• Telehealth and remote assessments can be used for study follow-up to maintain the integrity of HF clinical trial activities. Available technology should be utilized by investigators and co-ordinators to minimize missing study data with the caveat that there are no safety issues and that the temporary follow-up measures do not affect the scientific validity of the trial. There may also be options to assess factors such as the physical abilities of the study participants at home via smart phone applications.

• Delayed in-person procedures should be considered where attendance in person for assessment is unavoidable. Examples of this include: echocardiography and implantation of investigational study devices. In these cases, the option to delay attendance until the pandemic abates could be considered.

• Despite many institutional review boards being on hiatus, the authors recommend maintaining frequent interaction and contact with appropriate data safety monitoring boards and institutional review boards. All investigator, committee, and monitoring meetings can be switched to home-based attendance using appropriate technology.

• Statistical monitoring should account for analysis of results based on dates that begin and conclude with the end of the pandemic and take into account geographic variability in these dates. The introduction of monitoring methods to remotely evaluate trial safety and conduct is recommended.

• Going forward, the pandemic is expected to have a negative impact on enrolment of future participants in clinical trials due to the need for in-person site visits as part of the process. Although the authors endorse suspension of in-person attendance, they recommend that the patient screening architecture for HF clinical trials is maintained so that once the pandemic has passed, enrolment can be re-instated with relative ease.

• Further consideration should be given to the geographic targeting of trial sites that are less likely to be affected by the pandemic, as this may help to recommence trial enrolment and preserve study momentum once the pandemic abates.

Abraham notes that the telehealth approach was rapidly and successfully employed at Ohio State University for research personnel to be able to continue to screen patients using electronic health records and to conduct remote follow-up. He says: 'Our aim with the collaboratory statement in JACC Heart Failure is not to replace official regulatory advice but ultimately to give some direction and stimulate debate about how to move forward consistent with the core principles of clinical research which emphasize the importance and well-being of those involved. We are trying to provide some directional leadership on what to do with these trials and how to preserve what we have so far. Of course, of primary importance is making sure that patients and researcher team members are safe during this time, but we would also seek to protect the integrity of the clinical trial to make sure that the data at the end of the day are alive and we know how to interpret them'.

Work is currently ongoing with an international group sponsored by the Heart Failure Association of the ESC towards the publication of an expert consensus document on HF clinical trials during the COVID-19 pandemic. The ESC website also contains up to date sources of information on all aspects of cardiovascular disease and research to support the community during these difficult times.

Heart failure collaboratory statement on clinical trials in the landscape of COVID-19